© 2023 MJH Life Sciences and CURE - Oncology & Cancer News for Patients & Caregivers. All rights reserved.
© 2023 MJH Life Sciences™ and CURE - Oncology & Cancer News for Patients & Caregivers. All rights reserved.
Shared insight on the current treatment landscape for myeloproliferative neoplasms (MPNs), including novel therapies for essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF).
December 15th 2022
Experts Rami Komrokji, MD, and Ruben Mesa, MD, define myeloproliferative neoplasms (MPNs) and explain differences between essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF).
Key opinion leaders highlight different testing and workup methods involved in making an accurate diagnosis of myeloproliferative neoplasms.
December 22nd 2022
Centering their discussion on cornerstone therapies, expert hematologist-oncologists consider the treatment paradigms of essential thrombocythemia and polycythemia vera.
Switching their focus to myelofibrosis, Rami Komrokji, MD, and Ruben Mesa, MD, consider mainstay treatment options in this setting.
December 29th 2022
Comprehensive insight on the various healthcare team members a hematologist-oncologist may work with to optimize care of myeloproliferative neoplasms.
Expert perspectives on the possible adverse events patients may encounter while receiving treatment for myeloproliferative neoplasms.
January 5th 2023
Focusing on clinical trials and novel therapies, Rami Komrokji, MD, and Ruben Mesa, MD, share their hope for the future management of essential thrombocythemia and polycythemia vera.
Comprehensive discussion on the management of myelofibrosis, covering both monotherapy and combination therapy strategies.
January 12th 2023
Before closing out their program on myeloproliferative neoplasms, Rami Komrokji, MD, and Ruben Mesa, MD, discuss the potential for progression of MF to acute myeloid leukemia and highlight key treatment strategies.
Adjuvant Chemoradiotherapy Demonstrated Better Outcomes for Patients With Endometrial Cancer
As Rare Disease Day Approaches, I’m Reflecting on My MPN Diagnosis
First Patient Injected With Novel Radiotherapy in Phase 2b Trial for Brain Cancer
FDA Approves Orserdu for Some Patients with Metastatic Breast Cancer